Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493961 · ClinicalTrials.gov registry record · Phase 1
Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism
A Phase 1 study of Kallmann Syndrome and Idiopathic Hypogonadotropic Hypogonadism, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00493961: Completed Phase 1 study of Kallmann Syndrome and Idiopathic Hypogonadotropic Hypogonadism, sponsored by Massachusetts General Hospital.
NCT00493961 is a Phase 1 study of Kallmann Syndrome and Idiopathic Hypogonadotropic Hypogonadism that has completed, run by Massachusetts General Hospital. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493961, a Phase 1 study of Kallmann Syndrome and Idiopathic Hypogonadotropic Hypogonadism, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
Men with Idiopathic Hypogonadotropic Hypogonadism (IHH) lack a hormone called gonadotropin releasing hormone (GnRH). This hormone is important for starting puberty, maintaining testosterone levels, and fertility. The purpose of this study is to research the effects of treating IHH men with GnRH for 7 days.
Conditions Studied
Interventions
- DRUG gonadotropin releasing hormone (GnRH)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 1999-01 |
| Est. Completion | 2009-11-17 |
| Phase | Phase 1 |
What the finished NCT00493961 record still lists
NCT00493961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 3 conditions, with Kallmann Syndrome appearing as the primary indexed condition, and to 1 intervention - of which gonadotropin releasing hormone (GnRH) is the first listed.
NCT00493961 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00493961 about?
NCT00493961 is a clinical study titled "Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism". Men with Idiopathic Hypogonadotropic Hypogonadism (IHH) lack a hormone called gonadotropin releasing hormone (GnRH). This hormone is important for starting puberty, maintaining testosterone levels, and fertility. The purpose of this study is to research the effects of treating IHH men with GnRH for ...
What is the current status of trial NCT00493961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 1999-01. Estimated completion is 2009-11-17.
What conditions does trial NCT00493961 study?
This clinical trial studies the following conditions: Kallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency.
What interventions are being tested in trial NCT00493961?
The interventions under investigation include: gonadotropin releasing hormone (GnRH) (DRUG).
Who is sponsoring clinical trial NCT00493961?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00493961 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kallmann Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00493961's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia